Loading company…
RNAimmune, Inc. develops mRNA-based therapeutics and vaccines, including personalized cancer vaccines, from Gaithersburg, US.
Founded in 2020 and based in Gaithersburg, US, RNAimmune, Inc. develops mRNA therapeutics and vaccines, including personalized neoantigen vaccines for cancer and prophylactic vaccines for infectious diseases. The company raised USD 27.00 mn in Series A funding on March 29, 2022, from investors including Sirnaomics, Inc., Smooth River Wealth Management and Rotating Boulder Fund. It earns revenue through partnerships, licensing and milestone payments, and has licensed its RSV mRNA vaccine technology to Hualan Biological Vaccine Inc. CEO Dong Shen leads the company.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in